Johnson Matthey Acquires Capacity in Scotland
The Scottish plant was built by Glaxo in 1980 and will be refurbished in 2015.
Johnson Matthey announced completion of an acquisition of pharmaceutical manufacturing capacity in Scotland. The 109,000-m2 site was acquired to meet increasing demand for custom pharmaceutical services and active ingredients using enhanced manufacturing capabilities.
Located in Annan, Dumfries and Galloway, the site was originally commissioned and constructed by Glaxo in 1980 and was most recently owned by Bakhu Pharma. A multimillion-pound refurbishment will begin in early 2015 to update and enhance the operational and quality standards of the facility. The site is expected to be fully operational by early 2016.
“This strategic site addition significantly increases our global manufacturing capabilities and capacity,” said John Fowler, division director at Johnson Matthey Fine Chemicals, in a press release. “Combining the Annan site with our leading technologies will answer our customers’ needs for efficient production of pharmaceutical intermediates and APIs at the highest quality and compliance standards in the market."
Source: Johnson Matthey
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
